TTrialPathMatch Me to Trials
← Back to trials
RecruitingAdvanced Solid Tumors

Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors

Eligible age

18+ yrs

Accepts

All genders

Locations

4 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The main goal of this first-in-human (FIH) study is to learn about the safety and dosing of GS-2121 when given alone or in combination with zimberelimab (ZIM) in participants with advanced solid tumors. The primary objectives of this study are: * To assess the safety and tolerability of GS-2121 as monotherapy and GS-2121 in combination with zimberelimab in participants with advanced solid tumors. * To identify the maximum tolerated dose (MTD) / maximum administered dose (MAD) and/or the recommended phase 2 dose (RP2D) of GS-2121 as monotherapy and in combination with zimberelimab in participants with advanced solid tumors.

Sponsor: Gilead Sciences

Where it's recruiting

California

Palo Alto

Texas

San Antonio

Virginia

Fairfax

Source: ClinicalTrials.gov · NCT06532565 · last updated 2026-04-21